miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity

PLoS One. 2014 Apr 11;9(4):e94382. doi: 10.1371/journal.pone.0094382. eCollection 2014.

Abstract

Cardiac hypertrophy is characterized by thickening myocardium and decreasing in heart chamber volume in response to mechanical or pathological stress, but the underlying molecular mechanisms remain to be defined. This study investigated altered miRNA expression and autophagic activity in pathogenesis of cardiac hypertrophy. A rat model of myocardial hypertrophy was used and confirmed by heart morphology, induction of cardiomyocyte autophagy, altered expression of autophagy-related ATG9A, LC3 II/I and p62 proteins, and decrease in miR-34a expression. The in vitro data showed that in hypertrophic cardiomyocytes induced by Ang II, miR-34a expression was downregulated, whereas ATG9A expression was up-regulated. Moreover, miR-34a was able to bind to ATG9A 3'-UTR, but not to the mutated 3'-UTR and inhibited ATG9A protein expression and autophagic activity. The latter was evaluated by autophagy-related LC3 II/I and p62 levels, TEM, and flow cytometry in rat cardiomyocytes. In addition, ATG9A expression induced either by treatment of rat cardiomyocytes with Ang II or ATG9A cDNA transfection upregulated autophagic activity and cardiomyocyte hypertrophy in both morphology and expression of hypertrophy-related genes (i.e., ANP and β-MHC), whereas knockdown of ATG9A expression downregulated autophagic activity and cardiomyocyte hypertrophy. However, miR-34a antagonized Ang II-stimulated myocardial hypertrophy, whereas inhibition of miR-34a expression aggravated Ang II-stimulated myocardial hypertrophy (such as cardiomyocyte hypertrophy-related ANP and β-MHC expression and cardiomyocyte morphology). This study indicates that miR-34a plays a role in regulation of Ang II-induced cardiomyocyte hypertrophy by inhibition of ATG9A expression and autophagic activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Autophagy / drug effects
  • Autophagy / genetics*
  • Base Sequence
  • Cardiomegaly / genetics*
  • Cardiomegaly / pathology*
  • Cardiomegaly / physiopathology
  • Disease Models, Animal
  • Gene Expression Regulation / drug effects
  • Humans
  • Male
  • Membrane Proteins / genetics*
  • Membrane Proteins / metabolism
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Molecular Sequence Data
  • Myocardium / pathology*
  • Myocardium / ultrastructure
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / ultrastructure
  • RNA, Small Interfering / metabolism
  • Rats, Sprague-Dawley
  • Systole / drug effects
  • Vacuoles / drug effects
  • Vacuoles / ultrastructure

Substances

  • ATG9A protein, rat
  • MIRN34 microRNA, rat
  • Membrane Proteins
  • MicroRNAs
  • RNA, Small Interfering
  • Angiotensin II

Grants and funding

Funding was supported by the Bureau of Science and Information Technology of Guangzhou Municipality (Grants Number: 2011J4300057 and 2012Y2-00027) and Bureau of Education of Guangzhou Municipality (Grants Number: 2012C230). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.